Trials / Active Not Recruiting
Active Not RecruitingNCT07226557
Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,000 (estimated)
- Sponsor
- National Institutes of Health Clinical Center (CC) · NIH
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a best available therapy treatment strategy.
Detailed description
please see uploaded study protocol
Conditions
- Carbapenem Resistant Bacterial Infection
- Acinetobacter Baumannii Infection
- Antimicrobial Drug Resistance
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2025-11-10
- Last updated
- 2025-11-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07226557. Inclusion in this directory is not an endorsement.